Quoin Pharmaceuticals to Announce Corporate Update and Fourth Quarter and Full-Year 2025 Financial Results on Thursday, March 26, 2026
Rhea-AI Summary
Quoin Pharmaceuticals (NASDAQ: QNRX) will provide a corporate update and release fourth quarter and full-year 2025 financial results before the market opens on Thursday, March 26, 2026.
The announcement will include an operational update highlighting key achievements from the quarter, recent accomplishments, and financial highlights from 2025, per the company.
Positive
- None.
Negative
- None.
News Market Reaction – QNRX
On the day this news was published, QNRX gained 5.36%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
QNRX fell 3.69%, while peers AZTR (-14.56%), JAGX (-8.04%), XRTX (-2.58%), CNSP (-2.65%) and XBIO (-0.32%) were also down, indicating broader weakness in small-cap biotech.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 11 | Fast Track designation | Positive | -1.1% | FDA granted Fast Track status to QRX003 for Netherton Syndrome. |
| Feb 26 | Awareness campaign | Positive | +0.1% | NETHERTON NOW campaign update highlighting growing disease awareness metrics. |
| Jan 27 | Japan ODD submission | Positive | -1.7% | Submission for Orphan Drug Designation and Fast Track review in Japan. |
| Jan 20 | Saudi breakthrough filing | Positive | +1.8% | Filed for Breakthrough Medicine Designation for QRX003 in Saudi Arabia. |
| Nov 11 | Pipeline expansion | Positive | +41.4% | Reported achieving target rapamycin loadings and plans for new clinical trials. |
Recent clinically positive and regulatory catalysts often saw mixed to negative next-day moves, with one notable large upside reaction to a pipeline expansion update.
Over the past several months, Quoin has focused on advancing QRX003 for Netherton Syndrome and expanding its pipeline. On Nov 11, 2025, shares reacted strongly to news of achieving target topical rapamycin loadings, rising 41.4%. In early 2026, multiple regulatory milestones followed, including a Japanese orphan drug submission on Jan 27 and a Saudi breakthrough designation filing on Jan 20. The Mar 11, 2026 Fast Track designation saw a modest -1.13% move. Today’s earnings date announcement comes against this backdrop of active clinical and regulatory progress.
Regulatory & Risk Context
An effective Form S-3 registration covers the resale of up to 10,045,455 ADSs by selling shareholders. The company will not receive proceeds from these resales but could receive up to $88.7 million if associated warrants are exercised for cash, and has highlighted potential dilution from the registered ADSs relative to ADSs outstanding.
Market Pulse Summary
The stock moved +5.4% in the session following this news. A strong positive reaction aligns with heightened interest ahead of the scheduled Q4 and full-year 2025 update. The company has recently delivered several regulatory and clinical milestones, including Fast Track status on Mar 11, 2026, which framed expectations entering this event. However, prior news sometimes saw mixed follow-through, so investors may have weighed dilution capacity from registered ADS resales and broader biotech volatility when assessing sustainability of any large gain.
AI-generated analysis. Not financial advice.
ASHBURN, Va., March 19, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it plans to provide a corporate update and release its financial results for the fourth quarter and full year ended December 31, 2025, before the market opens on Thursday, March 26, 2026.
The announcement will include an operational update highlighting key achievements from the quarter, recent accomplishments, and financial highlights from 2025.
About Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd. is a late clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin’s innovative pipeline comprises four products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, microcystic lymphatic malformations, venous malformations, angiofibromas and others. For more information, visit: www.quoinpharma.com or LinkedIn for updates.
For further information, contact:
Quoin Pharmaceuticals Ltd.
Michael Myers, Ph.D., CEO
mmyers@quoinpharma.com
Investor Relations
PCG Advisory
Jeff Ramson
jramson@pcgadvisory.com
(646) 863-6341
FAQ
When will Quoin Pharmaceuticals (QNRX) release its Q4 and full-year 2025 results?
What will Quoin Pharmaceuticals (QNRX) cover in its March 26, 2026 corporate update?
How can investors access Quoin Pharmaceuticals (QNRX) March 26, 2026 announcement?
Will Quoin Pharmaceuticals (QNRX) provide clinical program updates on March 26, 2026?
What date covers the financial results Quoin (QNRX) will report on March 26, 2026?
Is the Quoin Pharmaceuticals (QNRX) March 26, 2026 release expected before trading begins?
